Scholarlink

<p>Lornoxicam-loaded chitosan-coated Litsea lipid nanocarriers (LRX-CS-LLCs) were developed as an innovative oral delivery system, combining the synergistic anti-inflammatory effects of Litsea cubeba oil with the mucoadhesive properties of chitosan. The GC/MS analysis of <i>Litsea cubeba</i> oil identified <i>α</i>-citral (47.56%), <i>β</i>-citral (26.86%), and <i>D</i>-limonene (14.00%). Various LRX-loaded LLCs were prepared and optimized. Fourier transform-infrared (FTIR) and differential scanning calorimetry (DSC) confirmed its structural integrity. The optimized (LRX-CS-LLCs) exhibited a particle size of 165.4 ± 6.3&#xa0;nm, zeta potential of + 26.3 ± 3.2 mV, and entrapment effectiveness of 98.2%. In vitro release followed a controlled kinetic profile. In vivo, LRX-CS-LLCs significantly reduced carrageenan-induced paw edema (77 ± 1.86% inhibition) and PGE2, COX-2, and TNF-α levels by 4.4-, 3.6-, and 3-fold, respectively, compared to the positive control group. Histopathological examinations confirmed normal tissue architecture. Notably, LRX-CS-LLCs outperformed pure-LRX, marketed-LRX, and uncoated-LRX-LLCs, emphasizing its promise as an effective oral therapeutic approach for enhanced management of inflammatory conditions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Scouting the Efficacy of Chitosan-coated Litsea Lipid Carriers Nanoplatform as an Oral Delivery System of Lornoxicam in an Inflammatory Animal Model

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月29日

查看全文
  • Walaa A. El-Dakroury,
  • Abdelrahman R. Said,
  • Gihan F. Asaad,
  • Heba M. I. Abdallah,
  • Marwa E. Shabana,
  • Rahma A. Abdelsalam,
  • Eman M. Elsadek,
  • Basma H. Mohamed,
  • Yara S. Mohamed,
  • Sara M. Seliem,
  • Elsayed Y. Hamada,
  • Belal W. Attef,
  • Sara Saeed Kotb,
  • Shaza H. Aly

摘要

Lornoxicam-loaded chitosan-coated Litsea lipid nanocarriers (LRX-CS-LLCs) were developed as an innovative oral delivery system, combining the synergistic anti-inflammatory effects of Litsea cubeba oil with the mucoadhesive properties of chitosan. The GC/MS analysis of Litsea cubeba oil identified α-citral (47.56%), β-citral (26.86%), and D-limonene (14.00%). Various LRX-loaded LLCs were prepared and optimized. Fourier transform-infrared (FTIR) and differential scanning calorimetry (DSC) confirmed its structural integrity. The optimized (LRX-CS-LLCs) exhibited a particle size of 165.4 ± 6.3 nm, zeta potential of + 26.3 ± 3.2 mV, and entrapment effectiveness of 98.2%. In vitro release followed a controlled kinetic profile. In vivo, LRX-CS-LLCs significantly reduced carrageenan-induced paw edema (77 ± 1.86% inhibition) and PGE2, COX-2, and TNF-α levels by 4.4-, 3.6-, and 3-fold, respectively, compared to the positive control group. Histopathological examinations confirmed normal tissue architecture. Notably, LRX-CS-LLCs outperformed pure-LRX, marketed-LRX, and uncoated-LRX-LLCs, emphasizing its promise as an effective oral therapeutic approach for enhanced management of inflammatory conditions.